First-in-class drug approvals vs Antibody-drug conjugate trial starts in China
In 2025, first-in-class drug approvals in China stood at 11, against 177 for antibody-drug conjugate trial starts.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
First-in-class drug approvals and Antibody-drug conjugate trial starts
Unit: count · 10 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| First-in-class drug approvals | 2025 | Actual | 11 |
| First-in-class drug approvals | 2024 | Actual | 48 |
| First-in-class drug approvals | 2023 | Actual | 40 |
| First-in-class drug approvals | 2022 | Actual | 21 |
| Antibody-drug conjugate trial starts | 2025 | Actual | 177 |
| Antibody-drug conjugate trial starts | 2024 | Actual | 150 |
| Antibody-drug conjugate trial starts | 2023 | Actual | 120 |
| Antibody-drug conjugate trial starts | 2022 | Actual | 69 |
| Antibody-drug conjugate trial starts | 2021 | Actual | 40 |
| Antibody-drug conjugate trial starts | 2020 | Actual | 25 |
Shared periods
Side by side
4 periods are published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations charted in China · source organisations: NMPA, NHSA
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in China · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring